Lipoprotein(a) and heart failure. Another reason to study interventions in patients with very high levels of lipoprotein(a)?

JACC: Heart Failure

Volumn 4, Issue 1, 2016, Pages 88-89

  Ballantyne, Christie M ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Genetics; Heart failure; Lipoprotein(a); Lipoproteins

Indexed keywords

LIPOPROTEIN A;

ARTERIAL STIFFNESS; ARTERY COMPLIANCE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HEART INFARCTION; HUMAN; LIPOPROTEIN A GENE; NOTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION;

HEART FAILURE; HUMANS; LIPOPROTEIN(A);

EID: 84951863563     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.11.001     Document Type: Editorial

References (5)

1. Kamstrup P.R., Nordestgaard B.G. Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population. J Am Coll Cardiol: HF 2016, 4:78-87.
2. Albers J.J., Slee A., O'Brien K.D., et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013, 62:1575-1579.
3. Khera A.V., Everett B.M., Caulfield M.P., et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation 2014, 129:635-642.
4. Ferdinand K.C., Nasser S.A. PCSK9 Inhibition: discovery, current evidence, and potential effects on LDL-C and Lp(a). Cardiovasc Drugs Ther 2015, 29:295-308.
5. Tsimikas S., Viney N.J., Hughes S.G., et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015, 386:1472-1483.